Gene symbol
|
Fold changea
|
Tumors with prognosis gene signaturesb
|
Tumors from other microarraysc
|
---|
TIMP1
|
8.34
|
232
|
52
|
AARSd
|
4.48
| |
30
|
PEA15d
|
4.23
|
215
|
22
|
CD59
|
1.61
|
232
| |
IFITM1
|
3.03
| |
106
|
HMGB1d
|
2.07
|
215
|
496
|
RPN2d
|
1.91
| |
15
|
IGF2R
|
1.75
|
215
|
107
|
IGFBP3d
|
2.29
|
232
|
706
|
NPM1
|
2.60
|
87
|
679
|
NQO1d
|
3.77
|
55
|
200
|
TGFB1
|
2.35
| |
531
|
AKT1
|
3.33
| |
43
|
HYOU1d
|
2.16
| |
30
|
STAT1d
|
2.83
|
215
|
30
|
-
aThe fold changes of differential gene expression between Stage II CRC tumor and normal tissues were extracted from the microarray data presented in Fig. 1
-
bPrognosis gene signatures were extracted from the publication of Sanz-Pamplona et al., which surveyed 29 microarray studies with patient’s data of recurrence, metastasis and survival [25]
-
cAdditional microarray data from 50 previous publications was extracted from CRC tumor and metastatic specimens (Additional file 1: Table S3). The indicated number stands for tumor specimens with increased gene expression
-
dRefers to genes that are involved in transcriptional regulation (Fig. 3; Additional file 1: Table S1) and an overlapping with TCGA data (Additional file 2: Figure S2)